175 related articles for article (PubMed ID: 37740609)
1. Economic evaluation of prostate cancer risk assessment methods: A cost-effectiveness analysis using population data.
Mohammadi T; Guh DP; Tam ACT; Pataky RE; Black PC; So A; Lynd LD; Zhang W; Conklin AI
Cancer Med; 2023 Oct; 12(19):20106-20118. PubMed ID: 37740609
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.
Yun H; Kim J; Gandhe A; Nelson B; Hu JC; Gulani V; Margolis D; Schackman BR; Jalali A
JAMA Netw Open; 2023 Nov; 6(11):e2344856. PubMed ID: 38019516
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation.
Mowatt G; Scotland G; Boachie C; Cruickshank M; Ford JA; Fraser C; Kurban L; Lam TB; Padhani AR; Royle J; Scheenen TW; Tassie E
Health Technol Assess; 2013 May; 17(20):vii-xix, 1-281. PubMed ID: 23697373
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
[TBL] [Abstract][Full Text] [Related]
5. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
Dijkstra S; Govers TM; Hendriks RJ; Schalken JA; Van Criekinge W; Van Neste L; Grutters JPC; Sedelaar JPM; van Oort IM
BJU Int; 2017 Nov; 120(5):659-665. PubMed ID: 28370948
[TBL] [Abstract][Full Text] [Related]
7. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
Heijnsdijk EA; Denham D; de Koning HJ
Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Prostate-Specific Antigen Screening Among Chinese Men.
Zhao G; Shao Y; Zhang N; Wang J; Yuan L; Sun X; Shi L
Value Health Reg Issues; 2020 May; 21():272-279. PubMed ID: 32402819
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy in a population-based prostate cancer screening setting using a micro-simulation model.
Getaneh AM; Heijnsdijk EA; de Koning HJ
Cancer Med; 2021 Jun; 10(12):4046-4053. PubMed ID: 33991077
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study.
Govers TM; Hessels D; Vlaeminck-Guillem V; Schmitz-Dräger BJ; Stief CG; Martinez-Ballesteros C; Ferro M; Borque-Fernando A; Rubio-Briones J; Sedelaar JPM; van Criekinge W; Schalken JA
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):101-109. PubMed ID: 30127462
[TBL] [Abstract][Full Text] [Related]
11. Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men With Intermediate Prostate-Specific Antigen Levels in the United States.
Jiao B; Gulati R; Hendrix N; Gore JL; Rais-Bahrami S; Morgan TM; Etzioni R
Value Health; 2021 Aug; 24(8):1111-1117. PubMed ID: 34372976
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations.
Earnshaw SR; McDade CL; Black LK; Bell CF; Kattan MW
Pharmacoeconomics; 2010; 28(6):489-505. PubMed ID: 20196623
[TBL] [Abstract][Full Text] [Related]
13. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
[TBL] [Abstract][Full Text] [Related]
14. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
Littrup PJ; Kane RA; Mettlin CJ; Murphy GP; Lee F; Toi A; Badalament R; Babaian R
Cancer; 1994 Dec; 74(12):3146-58. PubMed ID: 7526969
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer.
Barnett CL; Davenport MS; Montgomery JS; Wei JT; Montie JE; Denton BT
BJU Int; 2018 Jul; 122(1):50-58. PubMed ID: 29388388
[TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
[TBL] [Abstract][Full Text] [Related]
19. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
20. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.
Martin AJ; Lord SJ; Verry HE; Stockler MR; Emery JD
Med J Aust; 2013 Jun; 198(10):546-50. PubMed ID: 23725269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
